Cardiovascular Safety Results from the Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)
Author Information
Author(s): ADAPT Research Group
Primary Institution: Johns Hopkins Bloomberg School of Public Health
Hypothesis
Can the NSAIDs naproxen sodium and celecoxib prevent Alzheimer's dementia and what are their cardiovascular risks?
Conclusion
The study suggests that while celecoxib does not show significant cardiovascular risk, naproxen may be associated with increased cardiovascular and cerebrovascular risks.
Supporting Evidence
- 28 out of 717 participants on celecoxib experienced cardiovascular events.
- 40 out of 713 participants on naproxen experienced cardiovascular events.
- 37 out of 1070 participants on placebo experienced cardiovascular events.
- Antihypertensive treatment was initiated in 160 out of 440 participants on celecoxib.
Takeaway
This study looked at whether two common pain relievers could help prevent Alzheimer's and found that one might be risky for the heart.
Methodology
A randomized, placebo-controlled trial with participants aged 70 and older, comparing celecoxib, naproxen, and placebo over a follow-up period.
Potential Biases
Participants had a family history of Alzheimer's, which may not represent the general population's risk factors.
Limitations
The trial was not primarily designed to examine safety, and it was stopped early, leading to small numbers of reported events.
Participant Demographics
Participants were aged 70 and older, predominantly Caucasian, with a high level of education.
Statistical Information
Confidence Interval
1.10 (0.67–1.79) for celecoxib; 1.63 (1.04–2.55) for naproxen.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website